1,721,105 research outputs found
Is thrombolysis for intermediate-risk pulmonary embolism beneficial? The case of Emeritus Professor Crow
No full textAn economic assessment of the use of abciximab as a coronary angioplasty preparation in the Italian health-care context
No full textEzetimibe/simvastatin 10/20 mg versus simvastatin 40 mg in coronary heart disease patients
Full text linkBACKGROUND: Reducing low-density lipoprotein cholesterol (LDL-C) is the primary goal of therapy
in patients with hypercholesterolemia and coronary heart disease (CHD).
METHODS: This double blind placebo-controlled study enrolled patients 18 to 75 years of age with primary
hypercholesterolemia and establishedCHDwhowere taking a stable daily dose of simvastatin 20 mg.
Patients were randomized to ezetimibe/simvastatin 10/20 mg (eze/simva; n 5 56) or simvastatin 40 mg
(simva; n 5 56) for 6 weeks. Percent change from baseline in LDL-C, total cholesterol, high-density lipoprotein
cholesterol (HDL-C), and triglycerides were assessed by use of the Student t test. The percent of
patients achieving LDL-C less than 100 mg/dL (,2.6mmol/L) or less than 80 mg/dL (,2.0 mmol/L) was
analyzed via logistic regression with terms for treatment, baseline LDL-C, age, and gender.
RESULTS: Baseline characteristics were similar between groups. Treatment with eze/simva combination
resulted in significantly greater reductions in LDL-C, total cholesterol, and triglycerides versus
doubling the dose of simva to 40 mg (all P , .01). Significantly more patients achieved LDL-C less
than 100 mg/dL (,2.6mmol/L) and less than 80 mg/dL (,2.0mmol/L) with ezetimibe/simvastatin versus
doubling the dose of simva to 40 mg (73.2% vs 25.0%; P,.001) for simvastatin. Changes in HDL-C were
similar between treatments. Both treatments were generally well tolerated.
CONCLUSION: In high-risk CHD patients with hypercholesterolemia, treatment with eze/simva combination
resulted in significantly greater reductions inLDL-C, total cholesterol and triglycerides, as well as
greater achievement of recommended LDL-C targets, compared with doubling the simvastatin dose to 40
mg over the 6-week period
Altered intraplatelet arachidonic acid metabolism during the acute state of unstable angina
No full text- …
